new york september 11, 2014 - nasdaqfiles.shareholder.com/downloads/coo/0x0x781231/... ·...

New York September 11, 2014

Analyst Meeting Presentation

2

2014 Analyst Meeting Forward Looking Statements

This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans,

prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including our 2014 and

2015 guidance and all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned

product launches and expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like

"believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking

statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties.

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes

in the global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing

uncertainty and instability of certain European Union countries that could adversely affect our global markets; foreign currency exchange rate and interest rate

fluctuations including the risk of fluctuations in the value of the yen, British pound and euro that would decrease our revenues and earnings; acquisition- related

adverse effects including the failure to successfully obtain the anticipated revenues, margins and earnings benefits of acquisitions, including the Sauflon acquisition,

integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the

measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse

impacts of contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or

refinancing of debt owed by us on a timely basis and on reasonable terms); a major disruption in the operations of our manufacturing, research and development or

distribution facilities due to technological problems, natural disasters or other causes; disruptions in supplies of raw materials, particularly components used to

manufacture our silicone hydrogel lenses; limitations on sales following product introductions due to poor market acceptance; new competitors, product innovations

or technologies; reduced sales, loss of customers, and costs and expenses related to recalls; new U.S. and foreign government laws and regulations, and changes in

existing laws, regulations and enforcement guidance, which affect the medical device industry and the healthcare industry generally; failure to receive, or delays in

receiving, U.S. or foreign regulatory approvals for products; failure to obtain adequate coverage and reimbursement from third party payors for our products;

compliance costs and potential liability in connection with U.S. and foreign healthcare regulations, including product recalls, warning letters, and potential losses

resulting from sales of counterfeit and other infringing products; legal costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement

related to product liability, patent protection or other litigation; changes in tax laws or their interpretation and changes in statutory tax rates; the requirement to

provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill; the success of our research and development

activities and other start-up projects; dilution to earnings per share from the Sauflon acquisition or other acquisitions or issuing stock; changes in accounting principles

or estimates; environmental risks and other events described in our Securities and Exchange Commission filings, including the "Business" and “Risk Factors” sections in

our Annual Report on Form 10-K for the fiscal year ended October 31, 2013, as such Risk Factors may be updated in quarterly filings.

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

3

2014 Analyst Meeting Management Introductions

Robert S. Weiss President & CEO The Cooper Companies

Daniel G. McBride, Esq. Executive Vice President, Chief Operating Officer & President of Cooper Vision, Inc.

Greg Matz Vice President & Chief Financial Officer The Cooper Companies

Carol R. Kaufman Executive Vice President, Secretary, Chief Administrative Officer & Chief Governance Officer The Cooper Companies

Albert G. White, III Vice President & Chief Strategy Officer The Cooper Companies

Fernando Torre Executive Vice President, Global Operations and Regulatory Affairs CooperVision, Inc.

Dennis Murphy Executive Vice President, Global Sales and Marketing CooperVision, Inc.

Paul L. Remmell President & CEO CooperSurgical, Inc.

Randal L. Golden General Counsel The Cooper Companies

2014 Analyst Meeting Agenda

4

Time Topic Presenter

8:00 – 8:05 FLS & Agenda Kim Duncan

8:05 – 8:20 Introduction Bob Weiss

8:20 – 9:00 CooperVision Dan McBride

9:00 – 9:30 CooperVision Commercial Dennis Murphy

9:30 – 9:50 CooperVision Operations Fernando Torre

9:50 – 10:10 CooperVision Q&A

10:10 – 10:25 Break

10:25 – 10:55 CooperSurgical Review Paul Remmell

10:55 – 11:25 Financial Overview Greg Matz

11:25 – 11:35 Closing Remarks Al White

11:35 – 12:00 Q&A

5

Robert S. Weiss President & CEO The Cooper Companies

2014 Analyst Meeting Company Overview

6 Source: Company reported data

Global Medical Device Company

Serving the specialty healthcare market through its business units: CooperVision (CVI)

and CooperSurgical (CSI)

NYSE: COO

HQ - Pleasanton, CA

~9,000 employees

FY13 Revenue: $1.6 billion

Investment Grade debt rating (S&P)

Keeping you at the forefront of women’s healthcareTM

7

2014 Analyst Meeting Our proven track record of success

What we told you in our

2010 IR Presentation What we delivered

Revenue growth exceeding the market Grew faster than the market in each

of the last 5 years

Maintain/expand gross margin Grew from 58% to 65%

Operating margin in the upper-teens Grew from 18% to 23%

Grow EPS faster than revenue Grew faster than revenue in each of

the last 5 years

Strong focus on free cash flow generation Generated more than $1.0B

cumulatively

Complete accretive acquisitions Closed ten acquisitions

2014 Analyst Meeting 5 Year Shareholder Value

8

Shareholder Return

Source: Yahoo Finance

0

100

200

300

400

COO ^GSPC (S&P 500)

9

Grow revenue faster than our

markets

Grow EPS faster than revenue

Generate over $1.3 billion in free cash flow

Expand CVI and CSI

geographically

Complete strategic

acquisitions

2014 Analyst Meeting Long Term Objectives (2014 – 2018)

2018E Operating

Margin of 26%+

2014 Analyst Meeting A Quality of Life CompanyTM

10

A big thank you to our #1 asset…

Our Employees

11

Daniel G. McBride, Esq. Executive Vice President, Chief Operating Officer, The Cooper Companies; President, CooperVision

12

CooperVision (CVI) is committed to crafting world-class lenses by listening closely to the needs of eye care professionals and lens wearers

World’s third largest manufacturer of soft contact lenses

~8,000 employees with products sold in over 100 countries

Headquartered in Pleasanton, CA

Major manufacturing sites in UK, Puerto Rico, Hungary and U.S.

Major distribution centers in UK, U.S. and Belgium

2014 Analyst Meeting CooperVision – Overview

13

2014 Analyst Meeting Global Market Share

Soft Contact Lens Market by Competitor Q2 CY14A

Source: Management estimates and independent market research

J&J 41%

Ciba 26%

Cooper 21%

B&L 9%

Other 3%

14

2014 Analyst Meeting Above Market Growth

Soft Contact Lens Market vs. CooperVision Sales Growth

Note: TTM14 is trailing twelve months through June 2014 Source: Company reported data and independent market research

CooperVision has consistently out performed the market

6%

4% 5% 5%

6%

10%

7%

11% 12%

10%

0%

2%

4%

6%

8%

10%

12%

CY10 CY11 CY12 CY13 TTM14

Worldwide Soft Contact Lens Market CooperVision

16.5% 16.8% 17.8%

18.8%

20.6%

CY10 CY11 CY12 CY13 Q2 CY14*

15

2014 Analyst Meeting Market Share Gains

Increased Market Share

* Calendar Q2 CY14 Source: Management estimates and independent market research

Market share gain drivers:

Silicone hydrogel – Biofinity®, Proclear® 1-Day, MyDay®, and now clariti® Steady performance in hydrogel category

0

200

400

600

800

1,000

1,200

1,400

2005 2006 2007 2008 2009 2010 2011 2012 2013

Co

op

erV

isio

n R

even

ue

($ m

illio

ns)

2014 Analyst Meeting History of Top-Line Growth

16

2005– 2013 CAGR: 7.8%

CooperVision has grown over the years through a combination of: Introductions of new technologies Strategic acquisitions

17

2014 Analyst Meeting Market Share by Geography

Note: Soft contact lens market share Source: Management estimates and independent market research

Americas EMEA Asia Pacific

#3 in the Americas Strong SiHy base –

Biofinity® and Avaira®; MyDay® and clariti® FDA approved

~43% of CVI sales

#2 in EMEA Strong SiHy base –

Biofinity®, clariti®, Avaira® and MyDay®

~38% of CVI sales

#3 in Asia Pacific Under-indexed but

growing much faster than market in certain locations (e.g. China)

~19% of CVI sales

Cooper 12%

Cooper 22%

Cooper 30%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Americas $3,046

40%

Americas $4,189

42%

Asia Pacific $2,263

30%

Asia Pacific $2,823

28%

EMEA $2,251

30%

EMEA $2,948

30%

CY14E CY19E

18

CAGR CY14E to CY19E

U.S. dollars in millions

2014 Analyst Meeting

6%

5%

7%

6%

EMEA

Asia Pacific

Americas

Soft Contact Lens Market by Geography

Total Market

Estimated 5-Year Sales Trend Soft Contact Lens Market by Geography

Note: Estimates are based on manufacturers’ sales Source: Independent market research and management estimates

$7,560 $9,960

19

2014 Analyst Meeting Market Share By Category

Note: Soft contact lens market share Source: Management estimates and independent market research

#3 in sphere Under-indexed in

1-Day lenses ~57% of CVI sales

#1 in toric Strong SiHy and

hydrogel portfolio ~32% of CVI sales

#1 in multifocal Strong SiHy and

hydrogel portfolio ~11% of CVI sales

Sphere Toric Multifocal

Cooper 16% Cooper

32%

Cooper 39%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Sphere 74%

Sphere 71%

Multifocal 6%

Multifocal 7%

Toric 20%

Toric 22%

CY14E CY19E


8%

10%

5%

20

Estimated 5-Year Sales Trend Soft Contact Lens Market by Category

CAGR CY14E to CY19E


6% Total Market

Soft Contact Lens Market by Category

Toric

Multifocal

Sphere


$7,560 $9,960

21

#3 in 1-Day Well positioned for

growth with clariti®, MyDay® and Proclear® 1-Day

#3 in FRP Well positioned for

growth with market-leading SiHy platform including specialty lenses

1-Day Modality FRP Modality

Cooper 15%

Cooper 25%

2014 Analyst Meeting Market Share By Modality

Note: Includes Sauflon

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Frequent Replacement

58%

Frequent Replacement

50%

1-Day 42%

1-Day 50%


22

Growth in key categories; 1 Day modality leading growth

Estimated 5-Year Sales Trend Soft Contact Lens Market by Modality

CAGR CY14E to CY19E


CY14E CY19E

$7,560 $9,960 6% Total Market

9%

3% Frequent Replacement

1-Day


Soft Contact Lens Market by Modality


23

Investing for future growth

Expanding CooperVision sites

Additional space to several key facilities

Additional production capacity

1-Day expansion and Biofinity® Growth

Adding New Sites

Costa Rica plant

Integrating Sauflon facilities

Scaling Capacity

Company description

Manufactures and distributes soft contact lenses and solutions, including a full suite of 1-Day silicone hydrogel products (sphere, toric and multifocal)

Product / geographic portfolio

Lead product: clariti® 1day (sphere, toric and multifocal)

– Received FDA clearance in August 2013; launched in the US in March 2014

Global presence with sales offices in over 10 countries and products sold in over 50 countries

Primary operations in UK and Hungary


24

Sauflon Acquisition - Overview

Consistent with CooperVision’s strategy to expand presence in underpenetrated areas – 1-Day silicone hydrogel lenses

1-Day silicone hydrogel lenses account for approximately $400M of the global $3.1B 1-Day market

Significantly accelerates CooperVision’s 1-Day franchise

Enables a multi-tier 1-Day strategy with a full suite of silicone hydrogel and hydrogel lenses available in all product categories (sphere, toric and multifocal)

Provides opportunities for segmented value proposition

Halo effect – selling existing products into new accounts given demand for 1-Day silicone hydrogels

Capitalizes on CooperVision’s global footprint to aggressively roll out clariti® 1day


25

Source: Management estimates

Sauflon Acquisition – Strategic Rationale

Sauflon has great momentum in 1-Day silicone hydrogel

Strong European presence and recent entry into the US

Proven technology with strong brand recognition

Once integrated into CooperVision, we expect to accelerate Sauflon’s growth

Ability to more aggressively roll out clariti® in the US and Asia Pacific utilizing existing infrastructure

Ability to support a more aggressive CapEx program to support multi-year growth


26

Cooper and Sauflon – A Winning Combination

Thoughts from our first month

Integration planning

Facility visits

Product analysis

Synergy opportunities

Personnel decisions

Manufacturing

Solutions business


27

Sauflon Acquisition

Everyone. Everyday.

People • Innovation • Product Portfolio • Customer Focus

28


New Product Introductions

2008 2009 2010 2011 2012 2013 2014

Proclear® 1-Day Biofinity® Toric Avaira® Toric Biofinity® Multifocal

Proclear® 1-Day Multifocal

MyDay® Biofinity® Toric XR

Avaira® Sphere Private Label 1-

Day Silicone Hydrogel

Biofinity® XR

ClearSight® 1-Day Toric

clariti®

Continued growth through new technologies

Product Portfolio

2014 Analyst Meeting Core Silicone Hydrogel Products

29

Biofinity® and Avaira®

Superior, long-lasting comfort and vision performance

Biofinity® - Full suite of monthly lenses

Avaira® - 2-week disposable sphere and toric

MyDay®

CooperVision’s premium 1-Day product

Launched in Europe and select Asia Pacific Market

FDA approved in the U.S.

clariti®

Mass market 1-day portfolio with broad parameter range

Sphere, Toric and Multifocal 1-Day lenses

Launched in EMEA, U.S. and select Asia Pacific locations


30

Driven by comfort and convenience

New technology focused on bringing innovation to a wider contact lens audience

Enhancing the user experience

Focus on bringing new technology to current wearers that improves the contact lens experience – material, design, modality

Lengthening current use of contact lens wear

Continued focus on the multifocal market – has huge potential

New Technology and R&D


31

More than just selling a product

Comprehensive portfolio

Private label

Value Add Services – support customers and enhance user experience

Eye Care Prime/Websystem3™

LensFerry™

Private Label

Customer Partnership


32

Summary:

1 • Strong Historical Market Growth

2 • Well Positioned for Continued Growth

3 • Actively integrating Sauflon

4 • The Future Looks Bright

33

Dennis Murphy Executive Vice President, Global Sales and Marketing CooperVision, Inc.

2014 Analyst Meeting Commercial Update

34


• Today CooperVision (CVI) is no longer JUST a specialty lens company

• CVI is consistently dedicated to the clinician

• Dedicated to growing the category as a Multinational Corp. (MNC)

• Partner – Plans and Execution

• Quality of Thought, People, Actions, Anticipate

• Comprehensive product portfolio

• MNC – Luxottica, Grand Vision

• Regional Strategic Accts.

• MNC Corporate Accts.

35


Shifts in consumer and eye care professional (ECP) preferences

Practitioners are moving to 1-Day for health and lifestyle benefits

Patients are motivated by ECP influence, convenience and health benefits

New technologies bringing improved silicone and improved specialty lenses

The third generation of silicone hydrogel technology has cracked the performance formula – delivering high Dk/t, white eyes, and improved comfort and wearing

J&J, Alcon and CooperVision all bringing specialty lenses to market in their 1-Day portfolios

1-Day Segment driving patient and revenue growth

1-Day Segment – Overview

Growth

1-Day revenue growth 3-5x greater than frequent replacement (FRP) growth

Over the next 10 years 65-70% of new contact lens patients are expected to enter the 1-Day segment

1-Day revenue per patient 4-6x greater than an FRP patient

Opportunity

Expand 1-Day segment by accelerating patient migration to mass and premium sector of the segment

First mover advantage - surround the market with segment value proposition

36


1-Day Segment – Growth Opportunity 2014 Analyst Meeting

Globally, 1-Day represents ~41% of total soft contact lens market, and grew 10% TTM vs. FRP at 3%

Totaling ~$3.1 billion in revenue

Source: Management estimates and independent market research Note: Based on manufacturer sales

37

Americas $2,990M

1-Day 60%

FRP 40%

Asia Pacific $2,235M

1-Day 46%

FRP 54%

EMEA $2,180M

1-Day Segment by Geography 2014 Analyst Meeting

1-Day 25%

FRP 75%

1-Day continues to be the fastest growing modality

10% global growth in calendar 2012 and 2013; 2% growth in FRP during 2012 and 2013

– 25% growth in 2013 for 1-Day silicone hydrogel; anticipated to grow over 20% per year to 2018

Today only 13% of 1-Day sales are silicone versus 71% of FRP sales

Market Growth by Geography in Calendar 2013

38

1. SCL refers to Soft Contact Lenses Source: Management estimates

Fastest growing modality in the global SCL1 market

1-Day Growth 2014 Analyst Meeting

Annual patient value (manufacturer sales)

FRP Patient

Average 1-Day patient

SiHy 1-Day patient

39

Patient Revenue and Profitability

1-Day revenue per patient up to 4-6x greater than an FRP patient


http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=TY02q-9QUaTE0M&tbnid=CgNsOZdjOajJ8M:&ved=0CAUQjRw&url=http://www.webdesign.org/photoshop/drawing-techniques/people-icons.12700.html&ei=aHlgUpIQz6XgA6ihgZAB&bvm=bv.54176721,d.dmg&psig=AFQjCNHn4SCfBOQc6YwPAc0IDcymGki2Tg&ust=1382140561192652



40

2014 Analyst Meeting 1-Day SiHy Focus

CVI Today

CVI is the only manufacturer offering a full suite of 1-Day SiHy products

Sphere, toric, and multifocal – promotes a high level of practitioner

confidence in fitting “everyone”

Positioned with price and performance top of mind for both

practitioner and consumer

CVI Opportunities

2015 is the time for the U.S.

Europe continues it’s MyDay® launch, while also focusing on clariti®

Asia Pacific opportunities will develop with regulatory approval and

increases in manufacturing capacity

41

2014 Analyst Meeting 1-Day Segment

Source: Management estimates and independent research

Tipping point for silicone hydrogel (SiHy) success

$0

$500,000

$1,000,000

$1,500,000

$2,000,000

$2,500,000

2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021

1-Day Sphere

Segment Value Proposition

from CooperVision®

Limited migration after 5+ yrs in SiHy Mass migration with accelerated growth in SiHy

100%

80%

60%

40%

20%

42

About 8 out of 10 patients are still in legacy products

RETAIL PRICE

LE

NS

PE

RF

OR

MA

NC

E

Mass Market

Economy

Premium

Opportunity

Gap

Opportunity

Gap

Hydrogel

Hydrogel Hydrogel

Hydrogel Hydrogel

Hydrogel Hydrogel

Hydrogel SiHy

SiHy

2014 Analyst Meeting 1-Day Landscape

1-Day Landscape — today

43

Leveraging our new 1-Day portfolio to help them adopt silicone hydrogel

Products to meet every wearer’s demands

Hydrogel Hydrogel

Hydrogel

Hydrogel Hydrogel

Hydrogel

RETAIL PRICE

LE

NS

PE

RF

OR

MA

NC

E

Mass Market

Economy

Premium

Hydrogel

SiHy

SiHy

2014 Analyst Meeting 1-Day Innovations

44


Advanced Innovation Smart Silicone chemistry

Affordable Innovation AquaGen Technology

Specs Measure

Dk/t 100

Water Content 54%

Modulus 0.4Mpa

UV Protection Yes

Specs Measure

Dk/t 86

Water Content 56%

Modulus 0.5Mpa

UV Protection Yes

Complete SiHy 1-Day portfolio

http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&docid=VXAVfzOjwLSyGM&tbnid=a-2OAJKa0CCmVM:&ved=0CAUQjRw&url=http://www.sauflon.co.uk/eye-care-professionals/products/clariti-1day&ei=TddgUuPOEI7b4AOroYH4BQ&bvm=bv.54176721,d.dmg&psig=AFQjCNEvh5Bsa7SgEs1rQKdutYgX3SVt1Q&ust=1382164677943884

45

2014 Analyst Meeting 1-Day Segment

Everyone. Everyday.

46

2014 Analyst Meeting 1-Day Focus


Key 1-Day Takeaways

1. 1-Day is the fastest growing segment with 10% TTM YOY growth; strong

growth expected to continue

2. 1-Day market is ready for a mass silicone hydrogel migration – with the

right product performance and value

3. The comprehensiveness of a 1-Day portfolio matters to the ECPs and

consumers

2014 Analyst Meeting Unilateral Pricing Policy

47

Unilateral Pricing Policy (UPP) allows the manufacturer to establish the minimum retail price to the consumer

Potential Benefits

May protect ECP’s retail price point from discounters who do not invest in the clinical education and fitting process

Perceived by some ECPs that UPPs show the contact lens manufacturers are dedicated to the ECP

Potential Downsides/Challenges Enforcement can be challenging Consumer activism may generate legislative backlash and negative public

perceptions May alienate larger customers who want greater pricing freedom and cross

marketing

2014 Analyst Meeting Pricing Update

48

CooperVision’s strategy is about more than just price Only large U.S. manufacturer that doesn’t have UPP in place

Will consider if and when appropriate in the future

Continue to prioritize and support the ECP through: Price strategies Private labeling capability Channel management disciplines Value add portfolio Digital marketing programs Consistent market position

2014 Analyst Meeting The CVI Value Add Portfolio

49

EyeCare Prime™ Premier offers the full value add portfolio and more

2014 Analyst Meeting Value Add Portfolio

50

August 15, 2014 – Announced U.S. beta release of LensFerry™ as part of its EyeCare Prime suite of value-added services to ECPs

LensFerry™ is an e-commerce contact lens ordering solution branded to a practice E-commerce contact lens ordering solution branded to a practice

Helps ECPs level the contact lens ordering playing field Helps ECPs increase their contact lens revenues Helps build patient relationships and improves compliance Helps patient save time through online-ordering

Fernando Torre Executive Vice President, Global Operations and Regulatory Affairs CooperVision, Inc.

51

2014 Analyst Meeting Global Operations Sites

Juana Diaz, Puerto Rico

Rochester, NY

Liege, Belgium

Tokyo, Japan

Adelaide, Australia

Madrid, Spain

Milan, Italy

Ashford, England

Fareham, England

Southampton, England

Budapest, Hungary

Southampton, England

52


Hamble

Chandlers Ford

Ashford

Fareham

Juana Díaz

Scottsville Alajuela (Q4 2015)

United Kingdom Puerto Rico

Costa Rica New York

Budapest

Hungary

53

CooperVision Manufacturing Sites


Expansion of CooperVision sites Puerto Rico operations:

New warehouse and secondary packaging building Conversion of old warehouse and support areas to manufacturing areas Building expansion (additional 60,000 sq. ft. of manufacturing space)

UK operations: New manufacturing facility in Chandlers Ford (“Speedwell”)

Costa Rica New manufacturing facility – Phase 1 projected to start operation at the end of 2015

Integration/expansion of Sauflon’s manufacturing facilities Fareham Budapest Ashford

Additional production capacity concentrated on: MyDay® manufacturing ramp up Clariti® 1day Biofinity® Hydrogel One Day products

54

Manufacturing Capacity Expansion


Production: Approx. 1 billion lenses per year Secondary Packaging: Over 640 million lenses per year Number of Employees: Approx. 1,600 employees Square Footage: 550,000 (once current expansions are completed)

55

Puerto Rico Manufacturing Operations

2014 Analyst Meeting Expansion of Puerto Rico Operations

New warehouse and

secondary packaging building

New clean room manufacturing areas in existing buildings

Phase G Expansion (60,000 sq. ft. of additional manufacturing space)

56

2014 Analyst Meeting Scottsville Manufacturing Operations

Focus: Lathed “Made to Order” or very low volume products Production: Over 10 million lenses per year Number of Employees: Approx. 460 Square Footage: 50,000

57

2014 Analyst Meeting UK Manufacturing – Original CVI Sites

Production: Over 600 million lenses per year Number of Employees: Approx. 1,800 Square Footage: Approx. 350,000 (after current expansion)

58

Warrior Close

R&D Facility

2014 Analyst Meeting Expansion of UK Operations

59

2014 Analyst Meeting UK Manufacturing – Fareham Operations

60

Production: Over 50 million lenses per year Number of Employees: Approx. 200 Square Footage: Approx. 22,000

2014 Analyst Meeting Budapest Manufacturing Operations

Production: Over 370 million lenses per year Number of Employees: Approx. 900 Square Footage: Approx. 142,000

61

Manufacturing site for Solutions Production: Over 30 million bottles per year Number of Employees: Approx. 170 Square Footage: Approx. 55,000

2014 Analyst Meeting UK Manufacturing – Ashford Operations

62

Being developed as a new high volume manufacturing facility to complement the existing manufacturing operations

Location: Coyol Free Trade Zone Industrial Park in Alajuela, Costa Rica

The facility will be gradually ramped up over a period of several years

Phase 1: Consists of a manufacturing building of approx. 100,000 sq. ft.

Phase 2: Adds an additional 100,000 sq. ft.

Space available for additional phases for a total of 400,000 sq. ft.

Project Status:

Building shell construction for Phase 1 is basically completed

Initiating work on building improvements

First production expected by the end of 2015

2014 Analyst Meeting Costa Rica Manufacturing Operations

63

Lot 53 (42,000 m2)

Abbott

Hologic Covidien

Volcano

St. Jude

Micro Vention

MOOG

Bean-One

Additional Space (46,000 m2)


21.7 Acres

Facility location (Coyol Free Trade Zone Park, Alajuela, CR)

64


Construction site – November 2013

65


Construction site – June 2014

66

Delta Park West Henrietta

Tokyo

United Kingdom New York

Japan

Liege

Belgium

2014 Analyst Meeting CooperVision Distribution Operations

67

Sevington

2014 Analyst Meeting West Henrietta Distribution Operations

Distributes: Approx. 490 million lenses per year Secondary Packaging: Approx. 165 million lenses per year Number of Employees: 415 Square Footage: 282,000

68

2014 Analyst Meeting Delta Park Distribution Operations

Distributes: Approx. 730 million lenses per year Secondary Packaging: Approx. 660 million lenses per year Number of Employees: 340 Square Footage: 140,000

69

2014 Analyst Meeting Liege Distribution Operations

Distributes: Approx. 190 million lenses direct to customers in the core European markets (France, Germany, Benelux, Austria, Switzerland and Scandinavia) Number of Employees: 180 Square Footage: 124,000 70

2014 Analyst Meeting Japan Distribution Operations

Facility located in Tokyo Distributes: Over 500 million lenses per year Operated by: Nippon Express, a 3rd party logistics provider Square Footage: 34,500

71

2014 Analyst Meeting Sevington Distribution Operations

Distributes: Over 400 million lenses and 30 million solution bottles per year Secondary packaging operation Number of Employees: 200 Square Footage: 70,000

72

0

400

800

1,200

1,600

2010 2011 2012 2013 2014*

Vo

lum

e o

f Le

nse

s (m

illio

ns)

* 2014 Forecasted manufacturing volume Source: Management estimates

+8%

+12%

Production levels increasing

+14%

+22%

+5%

2014 Analyst Meeting Manufacturing Volume Trend

73

* 2014 Forecasted manufacturing volume Source: Management estimates

Productivity per employee improving

2014 Analyst Meeting Manufacturing Productivity Trend

74

0

400

800

1,200

1,600

2,000

0

1,000

2,000

3,000

4,000

5,000

2010 2011 2012 2013 2014*

Vo

lum

e (m

illio

ns)

Hea

dco

un

t

Mfg. Volume Total Mfg. Headcount

2014 Analyst Meeting Key Operational Initiatives

Sauflon integration: We are evaluating manufacturing and distribution plans to maximize operational

capabilities over the coming years

Manufacturing capacity expansion: Complete expansion of existing manufacturing facilities Start up the new Costa Rica facility in 2015 Silicone Hydrogel 1-Day Capacity Ramp up

MyDay® Clariti® 1day

Continue investment in the development of advanced manufacturing processes and technology

Implementation of new systems and processes to increase the efficiency of our global supply chain and distribution operations

Continue the development of an operational culture based on continuous improvement: Lean manufacturing Six sigma

75

76


Break

77

Paul L. Remmell President & CEO CooperSurgical, Inc.

78

2014 Analyst Meeting CooperSurgical, Inc. – Agenda

• Brief overview of CooperSurgical

• Market / market focus

• Historical performance

• Growth drivers

• Future

CooperSurgical (CSI) is dedicated to providing medical devices and procedure solutions that improve the delivery of healthcare to women.

• Sells exclusively to medical professionals

• ~1,000 employees worldwide

• Headquartered in Trumbull, CT

• Core operations in U.S. and Denmark

79

2014 Analyst Meeting CooperSurgical Overview

80

Follow medical professionals

Ob/Gyn offices

Hospitals

Women’s health clinics

Labor and Delivery suites

Fertility centers

Sales Business Units

Direct sales unit – offices

Operating room unit – hospitals, surgical centers

International Business Unit

IVF Business Unit (Origio)

Corporate Accounts Business Unit

2014 Analyst Meeting CooperSurgical Overview


55% 57% 58% 59% 59% 60% 64% 65% 66% 64%

$101 $108 $124

$154 $167 $170 $188

$210

$256

$319

48%

53%

58%

63%

68%

$0

$80

$160

$240

$320

2004 2005 2006 2007 2008 2009 2010 2011 2012 2013

Gro

ss M

argi

n P

erce

nta

ge

Co

op

erSu

rgic

al R

even

ue

(mill

ion

s)

Revenue Gross Margin %

Revenue and Gross Margin

2004– 2013 CAGR: 13.6%

81

82


88%

35%

69%

12%

65%

31%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Women's healthcare IVF Consolidated

Domestic International

Revenue

Source: Management estimates.

Pasadena, CA Charlottesville, VA

Mt. Laurel, NJ

Hilvarenbeek, The Netherlands

Ølstykke, Denmark

Måløv, Denmark*

* CSI Headquarters * ORIGIO Headquarters

Stafford, TX

Trumbull, CT*

83

Manufacturing Locations 2014 Analyst Meeting


CooperSurgical is a premier manufacturer of over 600 clinically relevant medical devices

Our market leading products are used by nearly all of women’s healthcare providers in clinics, operating rooms, labor and delivery suites, and reproductive (IVF) clinics worldwide

84

Product Offerings

Premier provider of women’s healthcare devices

Proven track record of successful M&A execution and integration

Completed over 30 acquisitions since inception in 1990

2014 Analyst Meeting Successful M&A Track Record

85

Successful M&A Track Record

86

Ob/Gyn visits are a significant segment of total patient visits

140 million Ob/Gyn patient visits annually (U.S. only)

Their complexity and variety requires a corporate partner with exceptional clinical expertise

CooperSurgical is that partner – we help manage this complex segment

Managing the challenging Ob/Gyn segment

Offering Exceptional Clinical Expertise 2014 Analyst Meeting

Our unique offering of 275 clinically-trained utilization specialists (IVF included) ensures products are optimally used for efficient care

Assurance of optimally managing women’s reproductive health – an important patient segment as women make most healthcare decisions for the family

Trusted Ob/Gyn products are the standard of care and used in most health-care facilities, bringing peace of mind to clinicians and administrators alike

87

Benefits of Working with CooperSurgical

Strategic Partnership 2014 Analyst Meeting

Surgery $1.6B

GYN Specific

, $1,000

General Use, $600

Obstetrics & Neonatal $510M

Office $1.7B

Total Estimated Market $4.310B

IVF $500M

Hospital, $2,110

IVF, $500

Office, $1,700


$80

$40

$150

$60

$120

$50

Needles &catheters

Sperm preparation

Media

Pipettes

Capital Equipment

Cryo/Vitrification

$270 $160

$80 Obstetrics

Neonatal

Breastfeeding

$400

$1,000

$50 $250

OfficeProcedures/Devices

Pharma Devices(IntrauterineSystems)

In-OfficeDiagnostic Testing

Cord Blood

88

Target Markets: Ob/GYN Specialty 2014 Analyst Meeting

Approx. market size – $1.7 billion

CooperSurgical currently participates in the office procedure space – approx. $400 million

Revenue in excess of $100 million

Market leader

Products used in everyday office visits

Primary products

General care

Cervical care

Family planning

Incontinence/ pelvic floor

Cryoablation

16,500 offices

Direct sales organization

68 FTE’s

89

Office Target Market 2014 Analyst Meeting

90

Currently undergoing a transition

Offices currently being acquired/consolidated

Physicians becoming employees

90

2000 2013 (projected)

2009 2005

57% 49%

43%

33%

1990

89%

Independent physicians as a percentage of total physicians

Source: Adapting to a new model of physician employment. Accenture. August, 2011

Office Market Dynamics 2014 Analyst Meeting

Consolidation means:

Office market currently in a state of transition

– Focus on acquiring

– Business as usual

– Transition to follow

Physicians transitioning from owner to employee

– Awaiting changes

– Everything on hold

– No decisions today

Procedure volume reported down

Effects from “Affordable Care Act”/Obamacare

Higher patient deductibles

Less discretionary dollars

Reimbursement

Continues to be an area of concern

91

Office Market Dynamics Continued 2014 Analyst Meeting

Slow to no procedure growth for the next few years, revenue to steady state thereafter – 3% to 5%

Consolidation to continue

Less call points

More sophisticated buyers

Demand more from vendors

– Smaller vendors unable to perform

Hospital associations taking control of purchasing

Standardization

Reliable vendors

Clinical support

Lower transaction costs

92

Our value proposition!

Office Market – Next 5 Years 2014 Analyst Meeting

Take advantage of our changing market place

Value proposition

Help standardization

Full clinical support

Meet needs of clinical buyer as well as economic buyer

Gain market share

Continue to promote the clinical value of our products

Become the choice for women’s healthcare

Transition sales organization towards National Account Management

Less focus on individual products

More focus on the CooperSurgical value proposition

Size the organization appropriately

93

Office Market Action Plan 2014 Analyst Meeting

Surgical target market is in excess of $2.0 billion

Revenue of $100 million

Made up of:

GYN-specific products

Specialty surgical instruments with crossover to general surgery

Current product line:

Sterilization products

Port-site closure products

Hysterectomy products

Laparoscopic instruments

Hybrid sales organization

65 FTE’s

63 Independent Representatives

Laparoscopic procedures growing 3% - 5%

Morcellation issues

Does not effect our product line directly

Endometrial ablation market continues to decline

Robot procedure volumes flatten

Value comes into question 94

Surgical Target Market 2014 Analyst Meeting

Drive market expansion

Port-site closure – 30% market penetration

Launch new products

4 new products currently in final stages of development

Market share gains

Expand product into distribution channel

Higher volume

Lower ASP

Fees

Look for specialty product acquisitions

Size and scale sales organization based on opportunities

95

Surgical Market Actions 2014 Analyst Meeting

Approx. 4.3 million annual births

Approx. 450,000 premature births

No major companies participate in this space

Many, many small players

Acquisition opportunities

Willing to pay for clinical improvements

No reimbursement issues

96

Labor & Delivery/Neonatal Market 2014 Analyst Meeting

In excess of $500 million in revenue annually

No major players

Many small

Currently have $10 million in annual revenue

Primary products

VAD (vacuum assisted delivery)

Dopplers

Infant Heel Warmers

Respiratory products

Specialty sales organization planned in FY 2015

8-10 FTEs

97

Target Markets: Ob/GYN Specialty 2014 Analyst Meeting

Establish a small specialty sales team

Explore acquisition targets

Product development opportunities

Produce line extensions

Next generation

New technologies

Plan is to obtain 20% market share

98

Labor & Delivery/Neonatal Next Steps 2014 Analyst Meeting

True worldwide opportunity

Same business model

Same protocols and procedures

Same use of products

Distinct/ unique call points

4,600 IVF clinics worldwide

Mostly stand-alone

Decision makers:

– IVF clinic manager

– Reproductive endocrinologist/ Fertility specialist

– Embryologist

High number of procedures

1.4 million fresh cycles

0.6 million frozen cycles

2.4 million IUI (intrauterine insemination)

Fairly high barrier to entry

Regulatory path

99

ART/IVF Market 2014 Analyst Meeting

Approximately $500 million in revenue

Origio currently has products that address 85% - 90%

Primary products:

Culture media

Oocyte (egg) retrieval

Embryo transfer catheters

Andrology (sperm analysis and preparation)

ICSI Pipettes

Vitrification (freezing and thawing of oocytes & embryos)

Ancillary products (lab products—dishes, glasses, etc.)

Time-lapse monitoring

Other lab equipment (workstations, microscopes, incubators, etc.)

Origio market leader

100

ART/IVF Market 2014 Analyst Meeting

101

Source: Internal Origio estimates

0%

5%

10%

15%

20%

25%

Origio Vitrolife Cook Irvine Wallace Kitazato Unisense Lifeglobal RI TPC Ksystem Others

Key IVF Medtech Players 2014 Analyst Meeting

Global market value ~$500 million/year

★ ★ ★

★

★ ★ ★

★

★

★

★

★

Australia

India

China Japan

Russia

Italy

Denmark

Spain

France

Germany

Benelux

U.K.

102

★ United States

Direct Sales and Marketing Presence 2014 Analyst Meeting

Market growth

Worldwide cycles expected to grow 6% - 7%

– Fresh cycles 3% - 4%

– Frozen cycles 8% - 10%

ASP expansion with move to frozen cycles

Geographic expansion

– New “Go Direct” markets – Turkey, Korea, Poland, Czech Republic, etc.

103

0

400,000

800,000

1,200,000

1,600,000

2,000,000Trends in U.S. IVF Cycles

fresh=new patients

ART/IVF Growth Drivers 2014 Analyst Meeting

Product line additions

– 1-Step Media

• Currently around 30% of media market

– Full line of Needles & Catheters

• Current market share at less than 5%

– Products currently under development

IVF Cycles Reported in 2013

Expected IVF Cycle Growth

Total Market Growth

China 161,000 12% 15%

Japan 155,000 0% 2%

USA & Canada 150,000 5% 8%

India 85,000 15% 20%

Russia 58,212 5% 11%

Germany 63,521 1% 3%

France 58,800 -2% -1%

Spain 48,000 0% 1%

Latino/ So. America 49,000 5% 11%

Italy 46,500 -7% -6%

UK 52,000 5% 6%

Australia 40,320 2% 5%

ROW 450,000 7% 10%

TOTAL ______________

2,000,000 ______________

6% - 7% ______________

8% - 10%

104

IVF Business Market Growth 2014 Analyst Meeting

Continued move to single embryo transfers

Reduces complications from multiple births

Less long-term side effects for women

Reduces costs by eliminating stimulation drugs

Freezing excess embryos

No reduction in success rates

Less costly than fresh cycle

Time Lapse Embryo Imaging

Assists in the selection of best embryos

– Monitors embryo development more precisely (not yet proven)

– Detects delays in embryo development, which indicates aneuploidy (chromosomal abnormality)

105

ART/IVF Trends 2014 Analyst Meeting

Product development

Many new and exciting opportunities

Origio has a world-class development team in place

Complete integration of all subs

All run independently today

Give them backend support

Evaluate additional “Go Direct” opportunities

Launch new products

1-Step

Needles and Catheters

BlastGen

Invest in sales and marketing to drive growth

Integrate all manufacturing activities

Improve margins 400 – 500 basis points

Leverage CSI core competencies

Discontinue non-strategic, low margin capital equipment

106

ART/IVF Next Steps for Origio 2014 Analyst Meeting

About one year ago, we started building our capabilities to develop products internally

Focused on both women’s healthcare business and IVF business

Not intended to be research driven, rather identify product line expansion products to fill our product portfolio and leverage our sales organization

First products to be launched from these efforts will be introduced over the next 6 months

Expected annualized revenue is in excess of $75 million from these initiatives in FY 2019

107

Product Development Initiative 2014 Analyst Meeting

ABBI™ Ally UPS

Advincula Arch – DSP Sacrocolpopexy tips

Launch Date

15 June 2015 Days until launch

285

Launch Date

17 November 2014 Days until launch

75

Launch Date

15 April 2015 Days until launch

224

Launch Date


69

Estimated revenue potential: $2.6 million




108

Product Developments 2014 Analyst Meeting

Embryo Transfer Catheters (full line) SAGE 1-Step

Oocyte Retrieval Needles Origio Sequential Media

Launch Date

15 January 2015 Days until launch

134

Launch Date

30 September 2015 Days until launch

392

Launch Date


82

Launch Date


348





109

All new products require country specific registration approvals

Origio Product Development 2014 Analyst Meeting

Well-positioned as the Women’s Healthcare Choice in changing market

Concentrate on focus markets

IVF

Labor & Delivery/ Neonatal

Establish product development capabilities

Leverage International infrastructure

Opportunity for women’s healthcare products

110

Going Forward 2014 Analyst Meeting

111

Greg Matz Vice President & Chief Financial Officer The Cooper Companies

112

Recent Events

Sauflon Update:

Accounting Update Closed acquisition on August 6, 2014 Closing books for the first time now

Proforma

Statements to be released on form 8-K within 75 calendar days of August 6th (by October 20th)

Will provide proforma information for FY 2013 and FY 2014 July YTD to include Sauflon incorporated in The Cooper Companies financials

Additional quarterly proforma information to be provided prior to Q4 earnings call

Taxes Plan to transfer part or all of Sauflon’s intellectual property into CooperVision’s

global tax structure ⁻ Transfer details (timing, amounts etc.) dependent on valuation work ⁻ Any transfer of intellectual property will generate tax obligations ⁻ All costs are acquisition-related, and will be excluded from non-GAAP EPS

Plan to implement new structure prior to calendar year-end


113

2014 Analyst Meeting Recent Events

Debt Structure:

Announced a new $700 million term loan in conjunction with Sauflon close

Investment grade rating by S&P (BBB-, negative watch)

Term Maturity Date Total Size

Revolver 5 Year May 31, 2017 $1,000M

Term Loan 5 Year Sept. 12, 2018 $300M

Term Loan (new) 3 Year Aug. 4, 2017 $700M

Total $2,000M

$1,159 7.2%

$1,332 14.9%

$1,445 8.6%

$1,588 9.9%

$1,733 9.1%

$0

$400

$800

$1,200

$1,600

2010 2011 2012 2013 2014E*

Rev

enu

e ($

mill

ion

s)

Revenue Growth Drivers:

Silicone hydrogel, 1-Day lenses and acquisitions

114

Revenue

Consistent Revenue Growth

CAGR: 10.6%

*2014E represents midpoint of management guidance of $1,725 -$1,740M as provided 9/04/14. Non-GAAP – Refer to our Reconciliation of Non-GAAP to GAAP Operating Results.

CAGR

CVI 9.7%

CSI 14.8%

TCC 10.6%


$693 $827

$924 $1,027

59.8%

62.1%

63.9%

64.7%

~65%

$0

$300

$600

$900

$1,200

2010 2011 2012 2013 2014E*

Gro

ss P

rofi

t (

$m

illio

ns)

115

Gross Profit and Gross Margin

Strong Gross Margin Improvement

Gross Margin Drivers:

Strong manufacturing efficiencies and favorable product mix e.g. Biofinity, offset by 1-Day, IVF and Sauflon

CAGR: ~13%

*2014E represents management guidance as provided 9/04/14. Non-GAAP – Refer to our Reconciliation of Non-GAAP to GAAP Operating Results.


37.2% 37.7%

38.8% 38.4%

3.0%

3.3%

3.6% 3.7%

1.6%

1.5%

1.7%

1.9%

41.8%

42.5%

44.0%

44.0%

Total OPEX ~43%

$0

$200

$400

$600

$800

2010 2011 2012 2013 2014E*

OP

EX (

$m

illio

ns)

SG&A R&D Amortization

116

2014 Analyst Meeting Operating Expense

Strong Investment in SG&A and R&D

Operating Expense Drivers:

Invested heavily in operating expenses from 2010-2013 to support new product launches and geographic expansion

CAGR: ~11%

*2014E represents management guidance as provided 9/04/14, includes historic amortization and Sauflon. Non-GAAP – Refer to our Reconciliation of Non-GAAP to GAAP Operating Results.

117

2014 Analyst Meeting Amortization

Amortization:

Amortization drops in 2015 related to the roll-off from two major acquisitions

Significant Drop in Amortization in 2015

Excludes Sauflon

$24

$30 $29

$22 $21

$0.38

$0.46 $0.44

$0.32 $0.29

$0.00

$0.10

$0.20

$0.30

$0.40

$0.50

$0

$8

$16

$24

$32

2012 2013 2014E 2015E 2016E

Am

ort

izat

ion

Exp

ense

($

mill

ion

s)

Total Amortization EPS Impact

$227 $281

$312 $358

19.6%

21.1%

21.6%

22.5%

~24%

$-

$100

$200

$300

$400

2010 2011 2012 2013 2014E*

Op

erat

ing

Inco

me

($m

illio

ns)

118

2014 Analyst Meeting Operating Income and Operating Margin

Strong Operating Margin Improvement

Operating Income Drivers:

Consistent revenue growth and gross margin expansion have driven operating margin improvements In 2013 and 2014, began to see SG&A leverage

CAGR: ~16%


2018 OM Target Excluding

Amortization and with Sauflon

26%+

Excludes amortization

119

2014 Analyst Meeting Effective Tax Rate

2014 Guidance: ETR 9.5-10.5%

Overall Tax Structure:

Large portion of intellectual property offshore in lower tax jurisdictions Majority of sales and manufacturing outside the U.S. in countries with lower tax rates Operations in over 35 countries, with differing tax laws Structure has gone through many successful reviews by tax authorities


15.7%

10.1% 9.7% 7.4%

16.7%

11.1% 10.7% 8.8%

9.5- 10.5%

0.0%

4.0%

8.0%

12.0%

16.0%

2010 2011 2012 2013 2014E*

Effe

ctiv

e T

ax R

ate

Reported ETR ETR Excluding Amortization

120

2014 Analyst Meeting Foreign Exchange

Foreign Exchange Impact

Foreign Exchange Drivers:

Major revenue impacts – Yen and Euro; major COGS impact - Pound

Based on current rates, we expect a negative year over year FX impact in 1Q, 2Q and 3Q FY 2015

Foreign Exchange Impact:

Negative impact of $0.40, $0.50 and $0.31 in 2012, 2013 and 2014, respectively Sauflon will increase FX exposure going forward

Yen GBP Euro

Aug-10 Aug-11 Aug-12 Aug-13 Aug-14 Aug-10 Aug-11 Aug-12 Aug-13 Aug-14 Aug-10 Aug-11 Aug-12 Aug-13 Aug-14

$3.10

$4.50 $5.16

$5.95

$3.38

$4.82 $5.54

$6.41 $7.39

$0.00

$2.00

$4.00

$6.00

$8.00

2010 2011 2012 2013 2014E*

No

n-G

AA

P E

PS

Non-GAAP Non-GAAP Excluding Amortization

121

2014 Analyst Meeting Earnings Per Share

Accelerated Earnings Growth Since 2010

CAGR: ~22%

*2014E represents midpoint of management guidance of $7.34 - $7.44 as provided 9/04/14, includes Sauflon and excludes amortization Non-GAAP – Refer to our Reconciliation of Non-GAAP to GAAP Operating Results.

EPS Drivers:

EPS drivers include revenue growth, gross margin improvements, operating expense leverage, lower tax rates and reduced interest expense

122

2014 Analyst Meeting Capital Expenditure

Increased Investment in Capital Expenditure

*2014E represents management guidance as provided 9/04/14.

Non-GAAP – Refer to our Reconciliation of Non-GAAP to GAAP Operating Results.

Capital Expenditure:

Major CapEx investments for 1-Day and Biofinity®

$74 $104 $100

$178

$200+ 6.4%

7.8% 6.9%

11.2%

12-13%

0.0%

3.0%

6.0%

9.0%

12.0%

15.0%

$0

$50

$100

$150

$200

$250

2010 2011 2012 2013 2014E

Cap

ital

Exp

en

dit

ure

($

mil

lio

ns)

Capital Expenditure % of Revenue

123

2014 Analyst Meeting Free Cash Flow

Strong Free Cash Flow

FCF Target 2014-2018

$1.3B


$194

$233 $230 $239

$200+

$0

$50

$100

$150

$200

$250

2010 2011 2012 2013 2014E

Free

Cas

h F

low

($

mil

lio

ns)

Free Cash Flow:

Strong improvements in operating cash offset by recent capital investments

124

Q4 2014

Guidance

FY14

Guidance

FY15

Guidance

TOTAL $477 - $490 $1,725 - $1,740 $2,000 - $2,060

CooperVision $395 - $405 $1,400 - $1,412 $1,675 - $1,715

CooperSurgical $82 - $85 $325 - $328 $325 - $345

Non-GAAP* $2.00 - $2.10 $7.34 - $7.44 $8.20 - $8.60

Sale

s EP

S

$ millions, except EPS

2014 Analyst Meeting Guidance

*Represents management guidance as provided 9/04/14. Non-GAAP – Refer to our Reconciliation of Non-GAAP to GAAP Operating Results.

125

2014 Analyst Meeting Additional Financial Commentary

Capital Deployment:

Invest in core business Strategic M&A Debt pay down Stock buyback

Share Buyback:

$500 million share repurchase program in place with $211.5 million remaining

availability

Repurchased approximately 2.8 million shares beginning in December, 2011 for $288.5 million under the current program

126

2014 Analyst Meeting Key Takeaways

1 • Solid revenue growth

2 • Improving operating margins

3 • Double-digit EPS growth

4 • Significant free cash flow generation

127

Albert G. White, III Vice President & Chief Strategy Officer The Cooper Companies

128

Grow revenue faster than our

markets

Grow EPS faster than revenue

Generate over $1.3 billion in free cash flow

Expand CVI and CSI

geographically

Complete strategic

acquisitions

2014 Analyst Meeting Long Term Objectives (2014 – 2018)

2018E operating

margin of 26%+

2014 Analyst Meeting 3 Key Takeaways

129

1 • Leadership

2 • Consistency

3 • Opportunity

2014 Analyst Meeting Q&A

130

Q&A

new york september 11, 2014 - nasdaqfiles.shareholder.com/downloads/coo/0x0x781231/... ·...

Documents